Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Bortezomib, a proteasome inhibitor with efficacy in multiple myeloma, is associated with thrombocytopenia, the cause and kinetics of which are different from those of standard cytotoxic agents. We assessed the frequency, kinetics, and mechanism of thrombocytopenia following treatment with bortezomib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lonial, Sagar, Waller, Edmund K., Richardson, Paul G., Jagannath, Sundar, Orlowski, Robert Z., Giver, Cynthia R., Jaye, David L., Francis, Dixil, Giusti, Sara, Torre, Claire, Barlogie, Bart, Berenson, James R., Singhal, Seema, Schenkein, David P., Esseltine, Dixie-Lee W., Anderson, Jessica, Xiao, Hugh, Heffner, Leonard T., Anderson, Kenneth C.
Format: Artigo
Idioma:Inglês
Publicat: The American Society of Hematology 2005
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895114/
https://ncbi.nlm.nih.gov/pubmed/16099887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-03-1173
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars